Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics

Figure 1 PRISMA flow diagram of literature search and study selection.

Figure 2 Forest plot of comparison. A: 5-aminosalicylic acid (5-ASA) vs placebo, outcome: Relapse at 6-12 months; B: 5-ASA vs placebo, outcome: Any adverse event; C: Once-daily 5-ASA vs conventional dosing, outcome: Relapse; D: 5-ASA vs placebo, outcome: Serious adverse event; E: 5-ASA vs comparator 5-ASA, outcome: Relapse.

Figure 3 Risk of bias summary - Robvis tool.